Cyclacel Pharmaceuticals, Inc. (CYCC)

NASDAQ: CYCC · IEX Real-Time Price · USD
1.38
-0.02 (-1.43%)
May 20, 2022 4:30 PM EDT - Market closed
Market Cap13.79M
Revenue (ttm)n/a
Net Income (ttm)-19.72M
Shares Out9.99M
EPS (ttm)-2.05
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume21,772
Open1.44
Previous Close1.40
Day's Range1.36 - 1.44
52-Week Range1.29 - 7.84
Beta1.39
AnalystsBuy
Price Target20.40 (+1,378.3%)
Earnings DateMay 11, 2022

About CYCC

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced le...

IndustryBiotechnology
Founded1992
CEOSpiro Rombotis
Employees2,019
Stock ExchangeNASDAQ
Ticker SymbolCYCC
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for CYCC stock is "Buy." The 12-month stock price forecast is 20.4, which is an increase of 1,378.26% from the latest price.

Price Target
$20.4
(1,378.26% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Cyclacel Pharmaceuticals to Release First Quarter 2022 Financial Results

BERKELEY HEIGHTS, N.J., May 04, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medi...

2 weeks ago - GlobeNewsWire

Cyclacel Announces Dosing of First Patient in Phase 1/2 Study of Oral Cyc140 in Patients With Advanced Solid Tumors a...

- CYC140, a Potent and Selective PLK1 Inhibitor to Be Evaluated as a Single Agent Across Multiple Solid Tumor and Lymphoma Types in Streamlined, Registration-Directed Study - - CYC140, a Potent and Sele...

1 month ago - GlobeNewsWire

Cyclacel Pharmaceuticals Announces Publication Confirming Fadraciclib Suppresses MCL1 and Synergizes With Venetoclax ...

-New Preclinical Data Highlight Fadraciclib's Apoptosis Enabling Mechanism in Leukemia-

1 month ago - GlobeNewsWire

Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results

-Initial Data from Phase 1/2 Study of Oral Fadraciclib in Solid Tumors Expected in First Half of 2022 –

1 month ago - GlobeNewsWire

Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2021 Financial Results

BERKELEY HEIGHTS, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative me...

1 month ago - GlobeNewsWire

Cyclacel Pharmaceuticals to Participate in 2022 BIO CEO & Investor Conference

BERKELEY HEIGHTS, N.J., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative med...

3 months ago - GlobeNewsWire

Cyclacel Pharmaceuticals Reviews 2021 Achievements And Announces Key Business Objectives for 2022

– Now Enrolling Patients in Two Registration-Directed Trials for Lead Candidate, Oral Fadraciclib –

4 months ago - GlobeNewsWire

Cyclacel Pharmaceuticals to Participate in Biotech Showcase 2022 Virtual Conference

BERKELEY HEIGHTS, N.J., Dec. 23, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative med...

4 months ago - GlobeNewsWire

Cyclacel Announces Dosing of First Patient in Phase 1/2 Study of Oral Fadraciclib in Patients With Leukemias or Myelo...

Next-Generation CDK2/9 Inhibitor Fadraciclib to Be Evaluated as a Single Agent and in Combinations in Streamlined, Registration-Directed Study Next-Generation CDK2/9 Inhibitor Fadraciclib to Be Evaluate...

6 months ago - GlobeNewsWire

Cyclacel Pharmaceuticals to Release Third Quarter 2021 Financial Results and Provide Business Update

BERKELEY HEIGHTS, N.J., Oct. 29, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative med...

6 months ago - GlobeNewsWire

Cyclacel Pharmaceuticals Presenting at Three Conferences in September

BERKELEY HEIGHTS, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative me...

8 months ago - GlobeNewsWire

Cyclacel Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update

- Announces First Patients with Solid Tumors Dosed with Oral Fadraciclib - - Additional Phase 1/2 Trials for Fadraciclib and CYC140 Expected to Follow - - Cash Runway to Early 2023 - - Conference Call S...

9 months ago - GlobeNewsWire

Cyclacel Announces Dosing of First Patient in Phase 1/2 Study of Oral Fadraciclib in Patients With Advanced Solid Tum...

-Next-Generation CDK2/9 Inhibitor Fadraciclib to Be Evaluated Across Multiple Solid Tumor and Lymphoma Types in Streamlined Registration-Directed Study- -Next-Generation CDK2/9 Inhibitor Fadraciclib to ...

10 months ago - GlobeNewsWire

Cyclacel Pharmaceuticals to Present at Ladenburg Thalmann's Virtual 2021 Healthcare Conference

BERKELEY HEIGHTS, N.J., July 07, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative med...

10 months ago - GlobeNewsWire

Cyclacel Pharmaceuticals Reports First Quarter 2021 Financial Results

- Announces IND Authorization by FDA for Fadraciclib, a CDK2/9 Inhibitor, in Solid Tumors -  - Recent Publication Reported that Overactive KRAS Mutants are Impeded by CDK9 Inhibition -  - Following Rece...

1 year ago - GlobeNewsWire

Cyclacel Pharmaceuticals to Release First Quarter 2021 Financial Results and Provide Business Update

BERKELEY HEIGHTS, N.J., May 05, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medi...

1 year ago - GlobeNewsWire

Cyclacel Pharmaceuticals Announces Closing of $14.5 Million Underwritten Public Offering and Full Exercise of Over-Al...

BERKELEY HEIGHTS, N.J., March 16, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative me...

1 year ago - GlobeNewsWire

Cyclacel to Present at the Oppenheimer 31st Annual Healthcare Conference

BERKELEY HEIGHTS, N.J., March 15, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative me...

1 year ago - GlobeNewsWire

Cyclacel Pharmaceuticals Presses Capital Raise Button

Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) priced an underwritten public offering of 1.81 million common shares at $7 per share, a discount of 11% on the last close price of $7.87 on Thursday. It will ...

1 year ago - Benzinga

Cyclacel Pharmaceuticals Prices $12.65 Million Underwritten Public Offering of Common Stock

BERKELEY HEIGHTS, N.J., March 12, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative me...

1 year ago - GlobeNewsWire

Cyclacel Pharmaceuticals Announces Proposed Public Offering of Common Stock

BERKELEY HEIGHTS, N.J., March 11, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative me...

1 year ago - GlobeNewsWire

Cyclacel Pharmaceuticals Announces Presentation at 2021 BIO CEO & Investor Digital Conference

BERKELEY HEIGHTS, N.J., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative med...

1 year ago - GlobeNewsWire

Cyclacel Pharmaceuticals Reviews 2020 Achievements and Announces Key Business Objectives for 2021

– Anticancer Activity of Fadraciclib Monotherapy in Patients with MCL1 Amplified Solid Tumors – – Appointment of Mark Kirschbaum, M.D. as Chief Medical Officer – – $7 Million Strategic Investment by Fun...

1 year ago - GlobeNewsWire

Cyclacel Pharmaceuticals to Present at Biotech Showcase™ Digital 2021

BERKELEY HEIGHTS, N.J., Dec. 30, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative med...

1 year ago - GlobeNewsWire

Cyclacel Pharmaceuticals to Release Third Quarter Financial Results

BERKELEY HEIGHTS, N.J., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) (Nasdaq: CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing innovative medic...

1 year ago - GlobeNewsWire